Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
Date:6/1/2009

CALGARY, June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim results of a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung were presented May 30, 2009 at the American Society of Clinical Oncology (ASCO) annual meeting. The meeting is being held in Orlando, Florida from May 29 to June 2, 2009.

The presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung" was delivered by Dr. Monica Mita, the study principal investigator at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The interim results demonstrate that the treatment has been well tolerated, with 15 of 36, or 42% of evaluable patients experiencing stable disease (SD) for more than 16 weeks, including five patients who have had SD for more than 24 weeks. One patient had SD for more than 80 weeks. Oncolytics reported on May 12, 2009, that full enrolment of 52 patients was completed, at which time nine patients were continuing on study.

"The ASCO data are very encouraging, both in terms of efficacy in patients with sarcoma, and in those with other tumor histologies in whom the IDD group are investigating various REOLYSIN regimens," said Dr. Frank Giles, Director, IDD, and Deputy Director, CTRC at UTHSCSA.

Additional REOLYSIN results presented

Two additional poster presentations covering positive results of REOLYSIN trials were also presented at the ASCO meeting on May 30, 2009.

Dr. Johann de Bono and colleagues delivered a poster presentation entitled "A Phase I Study of the Combination of Intravenous Reolysin (REO) and Gemci
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
2. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
3. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
4. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
5. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
6. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
7. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
8. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
10. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
11. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Aug. 7 SyntheMed, Inc. (OTC Bulletin Board: SYMD), ... of anti-adhesion products, announced today that REPEL-CV Bioresorbable Adhesion ... National Association for Children,s Heart Disorders, Inc. Michelle L. ... to inform parents of children with congenital heart defects ...
... , BOTHELL, Wash., Aug. 7 SCOLR Pharma, ... for the three and six months ended June 30, 2009. ... President and CEO, said, "We continue to advance discussions with a ... potential partners have been committing resources to due diligence and preliminary ...
... EXTON, Pa., Aug. 7 Kensey Nash Corporation today ... distribution rights, along with the trademark, inventory and other ... line. Under the terms of the agreement, the Company ... OsseoFit distribution agreement. Pursuant to the agreement, following a ...
Cached Biology Technology:REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 8Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 3
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... inexpensive land along coastlines for vacation homes and tourist hotels. ... that threatens the very coral reefs attracting tourists in the ... Research Institute and colleagues find that bacteria on coral reefs ... in seawater increases. , "I set up a seawater system ...
... Garvan Institute, in collaboration with Spanish scientists, have formulated ... normal growth controls, which may have far-reaching implications for ... found large regions of DNA are 'switched off' in ... the Garvan Institute, says: "These large regions ?referred to ...
... multifaceted study involving the Kuna Indians of Panama, ... chemical compound that is, in part, responsible, for ... chocolate products. , The researchers, who are from ... of Duesseldorf, Germany; and Harvard Medical School, hope ...
Cached Biology News:Cancer cells suppress large regions of DNA by a reversible process that can be tackled 2Heart-healthy compound in chocolate identified 2
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
...
... Materials for 15-20 enhancements when used as directed, ... Enhancement System is designed to amplify the desired signal ... for evaluating proteins with low expression., ... to blocking the membrane; 1x solution; 250 ml, ...
Applications: Western blotting ...
Biology Products: